Want to see SE:STIL full AI Analyst Report?

Stille AB (STIL) Price & Analysis

1 Followers

STIL Stock Chart & Stats

kr186.50

-kr9.00(-3.81%)

At close: Mar 06 4:00 PM EST

kr186.50

-kr9.00(-3.81%)

Day’s Range― - ―

52-Week Rangekr143.00 - kr283.00

Previous CloseN/A

Volume3.08K

Average Volume (3M)7.24K

Market Cap

kr2.26B

Enterprise Valuekr2.18K

Total Cash (Recent Filing)kr149.36M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)31.2

Beta0.28

Next Earnings

Oct 23, 2026

EPS Estimate

1.92

Next Dividend Ex-DateN/A

Dividend Yield1.62%

Share Statistics

EPS (TTM)8.09

Shares Outstanding8,985,447

10 Day Avg. Volume6,271

30 Day Avg. Volume7,240

Financial Highlights & Ratios

PEG Ratio-7.85

Price to Book (P/B)2.48

Price to Sales (P/S)3.10

P/FCF Ratio113.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)8.97

Revenue Forecast (FY)kr723.50M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free structure and large equity base materially reduce financial risk, interest burden and refinancing needs. This gives Stille resilience to operating volatility and preserves flexibility to fund product development, capacity or acquisitions over the next several months.

Strong Revenue And Earnings GrowthStrong reported revenue and EPS growth indicates improving demand and operating leverage in Stille’s precision surgical instruments and operating-room solutions. If sustained, this can expand its customer base and strengthen the company’s earnings-generation capacity.

Healthy ProfitabilityHigh gross margins and a positive net margin support reinvestment, absorb some cost pressure and demonstrate economic value in Stille’s specialized medical-technology products. The profile suggests the business has a viable foundation for continued profitable growth.

Bears Say

Uneven Free Cash FlowRecent free-cash-flow improvement is encouraging, but the sharp prior decline shows that cash conversion is less consistent than earnings. Persistent variability could constrain internally funded investment and make results more sensitive to working-capital or operating changes.

Margin VolatilityThe rebound supports a healthy business model, yet the year-to-year EBIT movement indicates that profitability is not fully stable. Continued margin swings could reduce earnings predictability and limit the durability of operating leverage as the company expands.

Moderate Capital EfficiencyStille’s conservative balance sheet is a strength, but ROE of roughly 8–9% indicates only moderate productivity from its substantial equity base. Unless returns improve, the company may generate less shareholder value per unit of capital than its growth profile suggests.

STIL FAQ

What was Stille AB’s price range in the past 12 months?

Stille AB lowest stock price was kr143.00 and its highest was kr283.00 in the past 12 months.

What is Stille AB’s market cap?

Stille AB’s market cap is kr2.26B.

When is Stille AB’s upcoming earnings report date?

Stille AB’s upcoming earnings report date is Oct 23, 2026 which is in 32 days.

How were Stille AB’s earnings last quarter?

Stille AB released its earnings results on Jul 23, 2026. The company reported kr2.295 earnings per share for the quarter, missing the consensus estimate of kr2.564 by -kr0.269.

Is Stille AB overvalued?

According to Wall Street analysts Stille AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Stille AB pay dividends?

Stille AB pays a Annually dividend of kr1.8 which represents an annual dividend yield of 1.62%. See more information on Stille AB dividends here

What is Stille AB’s EPS estimate?

Stille AB’s EPS estimate is 1.92.

How many shares outstanding does Stille AB have?

Stille AB has 8,985,447 shares outstanding.

What happened to Stille AB’s price movement after its last earnings report?

Stille AB reported an EPS of kr2.295 in its last earnings report, missing expectations of kr2.564. Following the earnings report the stock price went down -1.538%.

Which hedge fund is a major shareholder of Stille AB?

Currently, no hedge funds are holding shares in SE:STIL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Stille AB

Stille AB develops, manufactures, and distributes medtech products in Sweden and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut, eye, blepharoplasty, operating, vascular, tenotomy, and face-lift scissors; colon, gall duct, multi-purpose, tangential occlusion, peripheral vascular, and anastomosis clamps; skin and nerve hooks, retractors, rib spreaders, self-retaining and trachea retractors, and nasal specula; and dressing, diathermy, knot-holding, tissue, iris, dura, and vascular forceps under the STILLE, Fehling, and S&T brands. Its Surgical Tables segment provides C-arm tables, which are surgical tables used in ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular procedures under the imagiQ and MedStone brands. The company also offers instrument care education, repair and maintenance, and inspection services. Stille AB was founded in 1841 and is headquartered in Torshälla, Sweden.